Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-bo ...